No Data
No Data
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
Express News | BridgeBio Pharma Inc - Topline Data Readout From Interim Analysis Expected in 2025
Express News | BridgeBio Completes Enrollment of Fortify, Phase 3 Registrational Study of Bbp-418 in Limb-Girdle Muscular Dystrophy Type 2I/R9 (Lgmd2I/R9)
Reported Earlier, BridgeBio's Acoramidis Shows 42% Reduction in Mortality and Heart Hospitalizations in ATTR-CM Study, New Drug Application Under FDA Review
Express News | BridgeBio: Attribute-Cm Study Shows 42% Cut in Composite ACM and Recurrent Cvh Events at 30 Months Observed With Acoramidis Treatment Vs Placebo